PhRMA, like nearly every workplace in America, employs men and women who have proudly served this nation in its armed forces and who remain active in the reserves.
Most Recent Posts
Last week we talked a bit about how improved adherence can lead to better health and lower overall healthcare costs.
Today, NPR Blog is addressing the issue, reporting that only half of Americans take their prescription medicines as directed. They also share some recommendations from Express Scripts that are worth checking out.
I just addressed the Pharma IQ conference, Winning the War Against Counterfeiters, here in Amsterdam.
On Friday, Health Affairs Blog featured a post by health policy attorney Paul Kim that brought to light the overwhelming lack of attention on the life sciences when discussing innovation in America's policy arena.
We at PhRMA often talk about the drug development process: it typically starts with many thousands of compounds in the discovery phase, whittled down to five that make it to clinical trials, one of which will eventually gain FDA approval - and only two out of those 10 will ever recoup the average investment in R&D required to develop the drug and secure that regulatory approval.
We talk about how long it takes and how expensive the R&D process is - an average of $1.3 billion and 10 to 15 years.
Amidst today's flowers and chocolates and candlelight suppers, take a few moments to remember that the heart is a bit more complicated than pastel candy stamped "Be Mine."
Sure, you need it to love. But you also need it to live.
The American Heart Association has some great information on how to take better care of your heart, from nutrition to stress management to exercise.
Run an internet search of "counterfeit drugs." You'll be stunned by how many stories there are about the growing worldwide threat of counterfeit medicines.
As the first week of blogging from PhRMA wraps up, I thought it would be good to point back to a couple of posts that linked to some great information.
First, there's Meet the Chartpack, introducing a great resource that brings together a ton of useful information about America's biopharmaceutical research sector.
They can rest assured that America's biopharmaceutical research companies are working to create success stories for ALS (also known as Lou Gehrig's Diseases) and many other rare conditions.
Yesterday I referred to the impact of improved adherence to medicines on overall healthcare spending.
Derek Thompson over at The Atlantic had an interesting post on his blog the other day looking at how the growing population of 65 and older is driving communications related and other technologies as well as businesses to meet their special needs.
Welcome to The Catalyst, part of PhRMA's new home on the web.
Telling the story of the biopharmaceutical sector is a daunting task, one that we strive to accomplish daily at PhRMA.
One new resource that I'm finding especially helpful in this effort is PhRMA's new Chart Pack, which visually conveys the value of the biopharmaceutical research sector, whether that value is demonstrated by saving lives, saving jobs, or saving long-term healthcare dollars.
President Obama's been speaking passionately about the importance of innovation to our economy recently. I was struck by his State of the Union speech where he said that: "Innovation doesn't just change our lives, it's how we make our living." That pretty well captures something we in the biopharmaceutical research sector have been talking about for a long time.
On Monday, Senator Leahy highlighted President Obama's Chamber of Commerce remarks in which he called for a need to reform our patent system. We're quick to recognize that patents - along with other forms of intellectual property - are a crucial incentive to innovate; in other words, they facilitate the work required to turn an idea into a usable product.
We are looking forward to becoming a more active participant in the health care conversation via our new blog.
Our goal is simple and straightforward. We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you and learn together.
Think of this post as our commitment to you.